Nasal polyps treatment have shown great advances recently, and many more treatments are on the horizon. Nasal polyps are used to describe chronic rhinosinusitis associated with the formation of nasal polyps. Nasal polyps affect 2-4% of adults globally. About 50% of patients have existing allergies. Nasal polyps are semitranslucent, pale grey, grape-like, benign inflammatory lesions […]
Abrocitinib vs. Dupilumab for Atopic Dermatitis
Abrocitinib vs. Dupilumab will be an important question for many prescribing doctors with the expected FDA approval of abrocitinib soon. We have extensively discussed atopic dermatitis (eczema) in the past. For many years only topical therapies were available for this condition. Topical steroids are the mainstays of treatment, and after many years newer topical therapies […]
Xolair for Allergic Rhinitis-A recent study
Xolair for allergic rhinitis may become a future treatment option for patients. Currently Xolair which is an anti-IgE antibody is indicated for moderate to severe persistent asthma and chronic idiopathic urticaria. But the mechanism of action lends itself to treating allergic rhinitis. Allergic rhinitis is one of the most common and increasing diseases worldwide, affecting […]
Xolair for Nasal Polyps
The treatment of Xolair for nasal polpys is currently being investigated. Chronic sinusitis with nasal polyps is common and is estimated to affect up to 15% of the population. It is associated with adult onset asthma. Many patients have uncontrolled symptoms despite use of nasal steroids. Even after surgery up to 80% of patients can […]
Covid with Xolair, Nucala, Cinqair, Fasenra or Dupixent for Asthma
As Covid-19 continues to spread around the world, there are concerns that patients with asthma will be at higher risk or poorer outcomes. There is also concern about whether asthma treatments could worsen the risk of disease or severity. Currently, asthma is not in the top 10 comorbidities associated with Covid-19 fatalities, obesity, diabetes and […]
New Treatment for Hives being studied
The current only approved treatment for hives are antihistamines and Xolair (omalizumab). Omalizumab is approved for the treatment of chronic hives for those 12 years and older (it is approved for 6 years and older in asthma). New treatment for hives are on the horizon. Stepwise approach to Chronic Urticaria (Chronic Hives) Ligelizumab is a […]
Abrocitinib for Atopic Dermatitis by Pfizer
Abrocitinib is currently being developed by Pfizer for the treatment of atopic dermatitis (eczema). It is an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor. The JAK/STAT pathway is an important factor in inflammation and itch in atopic dermatitis. There are multiple receptors and signaling cascades involved in eczema related inflammation and itch, one of these […]
How does Dupixent work?
How does Dupixent work? Dupixent is currently indicated for patients who have atopic dermatitis, asthma and nasal polyps. Dupixent works by inhibiting IL4 and IL13 and it has improved outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). A recent study published in Allergy studied Dupixent’s local effects on type 2 inflammatory biomarkers. The study […]
Omalizumab for Atopic Dermatitis
Omalizumab for atopic dermatitis has shown promising results. In JAMA Pediatrics, the researchers have demonstrated for the first time that omalizumab, which neutralizes IgE, reduced disease severity and improved quality of life in pediatric patients with severe atopic dermatitis. This was the case even in subjects with very high baseline total plasma IgE levels. Omaizumab […]
Future Eosinophilic Esophagitis Treatment Options
Future eosinophilic esophagitis treatments are currently in development. There are currently on FDA approved medications for the treatment of EoE. Commonly used treatments now are proton pump inhibitors, swallowed or topical corticosteroids and food elimination diets. Although each of these options is effective, there are limitations. Swallowed steroids can control inflammation 70-80% of the time, […]